CA2206333A1 - Novel anthracycline compound derivative and pharmaceutical preparation containing the same - Google Patents
Novel anthracycline compound derivative and pharmaceutical preparation containing the sameInfo
- Publication number
- CA2206333A1 CA2206333A1 CA002206333A CA2206333A CA2206333A1 CA 2206333 A1 CA2206333 A1 CA 2206333A1 CA 002206333 A CA002206333 A CA 002206333A CA 2206333 A CA2206333 A CA 2206333A CA 2206333 A1 CA2206333 A1 CA 2206333A1
- Authority
- CA
- Canada
- Prior art keywords
- anthracycline
- pharmaceutical preparation
- block copolymer
- high molecular
- polymer segment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940045799 anthracyclines and related substance Drugs 0.000 title abstract 7
- 239000000825 pharmaceutical preparation Substances 0.000 title abstract 5
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 239000002246 antineoplastic agent Substances 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 3
- 229940079593 drug Drugs 0.000 abstract 3
- 229920001400 block copolymer Polymers 0.000 abstract 2
- 239000000539 dimer Substances 0.000 abstract 2
- 229920001477 hydrophilic polymer Polymers 0.000 abstract 2
- 230000002209 hydrophobic effect Effects 0.000 abstract 2
- 229920001600 hydrophobic polymer Polymers 0.000 abstract 2
- 239000000693 micelle Substances 0.000 abstract 2
- 239000013638 trimer Substances 0.000 abstract 2
- 101100005765 Arabidopsis thaliana CDF1 gene Proteins 0.000 abstract 1
- 101100007579 Arabidopsis thaliana CPP1 gene Proteins 0.000 abstract 1
- 239000003513 alkali Substances 0.000 abstract 1
- 230000001093 anti-cancer Effects 0.000 abstract 1
- 230000000857 drug effect Effects 0.000 abstract 1
- 231100000053 low toxicity Toxicity 0.000 abstract 1
- 210000002381 plasma Anatomy 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A dimer, trimer or tetramer of an anthracycline compound which can be obtained by directly, chemically bonding anthracycline compounds having anticancer activities to each other by an alkali treatment.
A high molecular block copolymer-drug complex pharmaceutical preparation in which the high molecular block copolymer having a hydrophilic polymer segment and a hydrophobic polymer segment forms a micelle having the hydrophilic segment as its outer shell and contains in its hydrophobic inner core a dimer, trimer or tetramer of anthracycline compound alone or together with other drugs.
A high molecular block copolymer-drug complex pharmaceutical preparation in which the high molecular block copolymer having a hydrophilic polymer segment and a hydrophobic polymer segment forms a micelle having the hydrophilic segment as its outer shell and contains in its hydrophobic inner core an anthracycline anticancer agent, wherein, when the pharmaceutical preparation is intravenously administered to a CDF1 mouse, the amount of the anthracycline anticancer agent in 1 ml of the mouse blood plasma after 1 hour of its administration becomes 10 (% of dose/ml) or more, provided that the amount of anthracycline anticancer agent in the administered preparation is defined as 100.
The aforementioned pharmaceutical preparations have high drug effects and low toxicities.
A high molecular block copolymer-drug complex pharmaceutical preparation in which the high molecular block copolymer having a hydrophilic polymer segment and a hydrophobic polymer segment forms a micelle having the hydrophilic segment as its outer shell and contains in its hydrophobic inner core a dimer, trimer or tetramer of anthracycline compound alone or together with other drugs.
A high molecular block copolymer-drug complex pharmaceutical preparation in which the high molecular block copolymer having a hydrophilic polymer segment and a hydrophobic polymer segment forms a micelle having the hydrophilic segment as its outer shell and contains in its hydrophobic inner core an anthracycline anticancer agent, wherein, when the pharmaceutical preparation is intravenously administered to a CDF1 mouse, the amount of the anthracycline anticancer agent in 1 ml of the mouse blood plasma after 1 hour of its administration becomes 10 (% of dose/ml) or more, provided that the amount of anthracycline anticancer agent in the administered preparation is defined as 100.
The aforementioned pharmaceutical preparations have high drug effects and low toxicities.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP253404/95 | 1995-09-29 | ||
| JP25340495 | 1995-09-29 | ||
| PCT/JP1996/002789 WO1997012895A1 (en) | 1995-09-29 | 1996-09-26 | Novel anthracycline compound derivatives and medicinal preparations containing the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2206333A1 true CA2206333A1 (en) | 1997-04-10 |
| CA2206333C CA2206333C (en) | 2006-03-14 |
Family
ID=36095727
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002206333A Expired - Fee Related CA2206333C (en) | 1995-09-29 | 1996-09-26 | Novel anthracycline compound derivative and pharmaceutical preparation containing the same |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2206333C (en) |
-
1996
- 1996-09-26 CA CA002206333A patent/CA2206333C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2206333C (en) | 2006-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0795561A4 (en) | Novel anthracycline compound derivatives and medicinal preparations containing the same | |
| US5569670A (en) | Combination medications containing alpha-lipoic acid and related | |
| CN1840193B (en) | Nanometer capsule of anthracene nucleus anticancer antibiotic with polyethylene glycol-phospholipid | |
| AU2006275718B2 (en) | Pharmaceutical formulations/composition of guanfacine suitable for single dose form adminstration daily | |
| AU7718694A (en) | Improved pharmaceutical formulation | |
| CA2282082A1 (en) | Microgranules containing cisplatin | |
| US5985924A (en) | Metastasis suppressory agents | |
| CA2336945A1 (en) | Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate | |
| US5635515A (en) | Therapeutic agents for the treatment of multiple drug resistance of cancers | |
| WO1994005299A1 (en) | Medicinal composition | |
| CN100594902C (en) | Nano micelle preparation of Catharanthus roseus alkaloids antineoplastic drugs with coating of phospholipid derived from polyethylene glycol | |
| US3932624A (en) | Method for prolonging the inhibitory effect of saralasin on angiotensin II | |
| CA2382887A1 (en) | Immunopotentiating compositions | |
| JPH04243825A (en) | Remedy for pigmentation | |
| HUT70213A (en) | Antiemetic pharmateutilal preparations | |
| JPS5938203B2 (en) | A therapeutic agent for cerebral circulation disorders whose main ingredient is coenzyme Q. | |
| AU707467B2 (en) | Nasal administration of agents for treatment of delayed onset emesis | |
| CA2206333A1 (en) | Novel anthracycline compound derivative and pharmaceutical preparation containing the same | |
| CN101143146A (en) | Cefoperazone sodium and sulbactam sodium composition | |
| Levine et al. | Chloramphenicolâassociated encephalopathy | |
| US4343799A (en) | Use of derivatives of 6α-methylprednisolone for the prevention or reduction of adriamycin-induced cardiotoxicity | |
| CA2093258A1 (en) | Cytarabine ocfosfate hard capsule | |
| CA2283739A1 (en) | Ascorbic acid as an adjuvant in treatment of malignant tumors by chemotherapy and radiotherapy | |
| AU2001289762A1 (en) | Pharmaceutical extemporary compositions | |
| US6395717B1 (en) | Therapeutic drug for endotoxin blood symptom and multi-organ failure induced thereby |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20130926 |